o Tumor flare phenomenon defined as local pain, irritation, or rash localized at sites of known or suspected tumor. o Grade 3 Hgb decrease (< 8.0 g/dL) that is clinically manageable with blood transfusions or erythroid growth factor use does not require treatment discontinuation. o Grade 3 laboratory values that are asymptomatic or resolve to Grade ≤ 1 or baseline grade within 14 days. o Keratoacanthoma and squamous cell carcinoma of the skin. o Any endocrinopathy that can be medically managed with hormone replacement o Any grade 3 adverse drug reaction which can be medically managed with minimal risk to the participant (e.g. , placement of a pleural catheter for recurrent inflammatory pleural effusions) and resolves to at least grade one or baseline grade within 14 days. Criteria are based on the NCI Common Terminology Criteria for Adverse Events, Version 5. Where clinically appropriate subjects will receive one year of treatment during which subjects will be followed with surveillance scans every 6 -12 weeks. On a case by case basis treatment beyond a year is allowed per investigator discretion. Subjects with evidence of disease progression after completing a year of treatment will be allowed retreatment. Patents might be taken off treatment for disease progression prior to completing one year of treatment, but where clinically appropriate, treatment beyond radiographic progression is allowed if in the opinion of the investigator the subject is benefiting f rom treatment. Subjects will be taken off treatment if unacceptable toxicity occurs and is attributed to all therapeutic agents.